Association between the NBS1 Glu185Gln polymorphism and breast cancer risk: a meta-analysis

• Published in: Tumor biology 2013-04, Vol.34 (2), p.1255-1262
• Main Authors: Yao, Fan, Fang, Yue, Chen, Bo, Jin, Feng, Wang, ShuBao
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - etiology; Cancer Research; Case-Control Studies; Cell Cycle Proteins - genetics; Female; Genes; Genetic Predisposition to Disease; Humans; Meta-analysis; Nuclear Proteins - genetics; Polymorphism; Polymorphism, Genetic - genetics; Research Article; Risk Factors
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1007/s13277-013-0668-4

Nijmegen breakage syndrome 1 ( NBS1 ), a vital DNA repair protein in the homologous recombination repair pathway and a signal modifier in the intra-S phase checkpoint, plays a critical role in cellular response to DNA damages and the maintenance of genomic stability. The NBS1 Glu185Gln ( NBS1 E185Q, NBS1 8360G>C, rs1805794) polymorphism has been indicated to be involved in the development of cancer, but results of previous individual studies on the association between NBS1 Glu185Gln polymorphism and breast cancer risk remain controversial and inconclusive. Our meta-analysis investigated this association for the first time by pooling the odds ratios with corresponding 95 % confidence intervals (95 % CIs) of all individual publications available to date. Overall, 14 separate studies with 6,642 cases and 7,138 controls were finally included into the present meta-analysis after a comprehensive literature search of the PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases up to October 21, 2012. Overall analysis and subgroup analyses by ethnicity and source of controls were performed. Meta-analysis of total studies showed that the NBS1 Glu185Gln variant carriers were not susceptible to breast cancer (OR Gln vs. Glu  = 1.05, 95 % CI 0.80–1.39, P OR  = 0.719; OR Gln/Gln vs. Glu/Glu  = 0.82, 95 % CI 0.62–1.08, P OR  = 0.154; OR Glu/Gln vs. Glu/Glu  = 1.00, 95 % CI 0.90–1.13, P OR  = 0.939; OR Gln/Gln + Glu/Gln vs. Glu/Glu  = 0.96, 95 % CI 0.83–1.11, P OR  = 0.551; OR Gln/Gln vs. Glu/Glu + Glu/Gln  = 0.84, 95 % CI 0.67–1.05, P OR  = 0.134). Similar results were observed in heterogeneity-adjusted meta-analysis of all studies. Furthermore, subgroup analyses by ethnicity and source of controls did not identify any appreciable relationship of the NBS1 Glu185Gln polymorphism with breast cancer susceptibility in any populations. Sensitivity analysis by sequentially omitting individual studies confirmed the stability and reliability of our results. Our meta-analysis of currently available data shows no association between the NBS1 Glu185Gln polymorphism and breast cancer risk.